BACKGROUND: Hepatocyte growth factor plays an important role in tumor growth, metastasis and angiogenesis. C-met is HGF's high affinity receptor. AIM: The aim of the study was to assess the correlations between c-met expression and clinic-pathological factors in breast cancer tissues. Furthermore, the purpose of the study was to evaluate the prognostic value of the hepatocyte growth factor receptor (HGFR, c-met) expressions in homogenous group of breast cancer patients. MATERIALS AND METHODS: Tumor samples were collected from 302 patients with breast carcinoma treated with primary surgery. We have assessed the percentage of tumor cells with c-met expression, the intensity of reaction and the ratio of these two factors-immunoreactivity according to the Remmele score. RESULTS: We have observed no correlations between HGFR immunoreactivities and clinical parameters (tumor size, grade, axillary lymph node status, age). In 5-year observation we have found prognostic value of assessing c-met immunoreactivity in primary tumor. CONCLUSION: Our study has revealed prognostic value of c-met. Unlike in other authors' studies, our patients' group is very homogenous which might contribute to obtained results.
BACKGROUND:Hepatocyte growth factor plays an important role in tumor growth, metastasis and angiogenesis. C-met is HGF's high affinity receptor. AIM: The aim of the study was to assess the correlations between c-met expression and clinic-pathological factors in breast cancer tissues. Furthermore, the purpose of the study was to evaluate the prognostic value of the hepatocyte growth factor receptor (HGFR, c-met) expressions in homogenous group of breast cancerpatients. MATERIALS AND METHODS:Tumor samples were collected from 302 patients with breast carcinoma treated with primary surgery. We have assessed the percentage of tumor cells with c-met expression, the intensity of reaction and the ratio of these two factors-immunoreactivity according to the Remmele score. RESULTS: We have observed no correlations between HGFR immunoreactivities and clinical parameters (tumor size, grade, axillary lymph node status, age). In 5-year observation we have found prognostic value of assessing c-met immunoreactivity in primary tumor. CONCLUSION: Our study has revealed prognostic value of c-met. Unlike in other authors' studies, our patients' group is very homogenous which might contribute to obtained results.
Authors: P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: L Nakopoulou; H Gakiopoulou; A Keramopoulos; I Giannopoulou; P Athanassiadou; J Mavrommatis; P S Davaris Journal: Histopathology Date: 2000-04 Impact factor: 5.087
Authors: K Lindemann; J Resau; J Nährig; E Kort; B Leeser; K Annecke; A Welk; J Schäfer; G F Vande Woude; E Lengyel; N Harbeck Journal: Histopathology Date: 2007-07 Impact factor: 5.087